Fecha del CVA	13/12/2021

Parte A. DATOS PERSONALES

Nombre *	Anna		
Apellidos *	Gonzalez Neira		
Sexo *	Mujer	Fecha de Nacimiento *	07/09/1971
DNI/NIE/Pasaporte *	50100139K	Teléfono *	(34) 912246900 - 3350
URL Web			
Dirección Email	agonzalez@cnio.es		
Identificador científico	Open Researcher and Contributor ID (ORCID) *	0000-0002-5421-2020	
	Researcher ID		
	Scopus Author ID		

* Obligatorio

A.1. Situación profesional actual

Puesto	Jefe de Unidad		
Fecha inicio	2004		
Organismo / Institución	Centro Nacional de Investigaciones Oncológicas		
Departamento / Centro			
País		Teléfono	
Palabras clave			

A.3. Formación académica

Grado/Master/Tesis	Universidad / País	Año
Biomedicina	Universidad de Santiago de Compostela	2001
Licenciado en Ciencias Biológicas	Universidad Complutense de Madrid	1996

A.4. Indicadores generales de calidad de la producción científica

PUBLICATIONS IN WEB OF SCIENCE: 180; H-INDEX:50 ; AVERAGE IMPACT FACTOR (2016-2020):10.17
SUM OF TIMES CITED: 11093
ResearcherID https://publons.com/researcher/C-5791-2015/
ORCID: http://orcid.org/0000-0002-5421-2020

Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Since September 2004 I am heading the Human Genotyping Unit at CNIO, as part of the Spanish National Genotyping Center (www.cegen.org). In the Unit we offer researchers access to state-of-the-art methods for high throughput sequencing and genotytping for a wide range of applications. My job is focused on the coordination of the Unit's tasks, the implementation of new needs within the unit, project management and scientific advice. In addition, I play an important role in fundraising through national and international competitive projects and in the communication and establishment of effective collaborations with other researchers and institutions. In recent years, I have focused my efforts to facilitate the incorporation of genomics into clinical practice, working on the implementation of the pharmacogenetics in the SNS. My research activity at the CNIO has focused on the identification of genetic biomarkers influencing cancer susceptibility and drug response. I have been involved in many association studies (GWAS and recently TWAS) within the International Breast Cancer Consortium (coordinator: Douglas Easton), International Ewing Sarcoma consortium (coordinator: Olivier Delatree) and the International childhood Acute Lymphoblastic Leukaemia Genetics Consortium (coordinator: Richard Houlston). These studies, which involved the analysis of thousands of samples from

different countries, have allowed identifying several relevant risk alleles and results have been published in high-impact journals. I have been PI in seven national project and WP-PI in two European projects: Collaborative Oncological Gene-environment Study (COGS) co-leading the genotyping WP and currently the Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) project leading the Sequencing WP. I am executive broad Member of the Spanish Society for Pharmacogenetics and Pharmacogenomics (SEFF) and the National Representative and Board Member in the European Association for Predictive, Preventive and Personalised Medicine (EPMA). In 2012, my lab received by the National Accreditation Entity (ENAC) in recognition for both, their technical competence and their quality management the accreditation as a clinical laboratory, according to the specific requirements established in UNE EN ISO 15189:2007 standard, for large-scale SNP (Single Nucleotide Polymorphism) genotyping using high throughput technologies (No. 984/LE 1873) Member of ENAC (Entidad Nacional de Acreditación), Member of the Spanish Society of Human Genetics.

Parte C. MÉRITOS MÁS RELEVANTES

C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citaciones

1 Coignard J,; Lush M,; Beesley J,; O'Mara TA,. (50/100). 2021. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.Nat Commun. 2021 Feb 17;12(1):1078.

2 Dorlin L,Carvalho S, Allen J; Gonzalez Neira A; ; ;. (2/200). 2021. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women N Engl J Med 021 Feb 4;384(5):428-439.ISSN 1533-4406.

3 Johnson, Nichola; Maguire, Sarah; Morra, Anna; et al; kConFab Investigators. 2021. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers BRITISH JOURNAL OF CANCER. 124. ISSN 0007-0920.

4 Barnes, DR.; Rookus, MA.; McGuffog, L.; et al; González Neira, A.; Antoniou, AC.(72/194). 2020. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.Genetics in medicine. 22-10, pp.1653-1666. ISSN 1530-0366.

5 Peña Chilet, M.; Roldán, G.; Perez Florido, J.; et al; González Neira, A.; Dopazo, J.(12/32). 2020. CSVS, a crowdsourcing database of the Spanish population genetic variability.Nucleic acids research. ISSN 1362-4962.

6 Kramer, I.; Hooning, MJ.; Mavaddat, N.; et al; González Neira, A.; Schmidt, MK.(56/140). 2020. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.American journal of human genetics. ISSN 1537-6605.

7 Núñez Torres, R.; Martín, M.; García Sáenz, JÁ.; et al; González Neira, A. (AC). (14/14). 2020. Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.JAMA dermatology. ISSN 2168-6084.

8 Ruiz Pinto, S.; Pita, G.; Martín, M.; et al; González Neira, A. (AC). (20/20). 2020. Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.Clinical pharmacology and therapeutics. ISSN 1532-6535.

9 Feng, H.; Gusev, A.; Pasaniuc, B.; et al; González Neira, A.; Jiang, X.(96/252). 2020. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.Genetic epidemiology. 44-5, pp.442-468. ISSN 1098-2272.

10 Zhang, H.; Ahearn, TU.; Lecarpentier, J.; et al; González Neira, A.; García Closas, M.(88/272). 2020. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.Nature genetics. 52-6, pp.572-581. ISSN 1546-1718.

11 Kapoor, PM.; Mavaddat, N.; Choudhury, PP.; et al; González Neira, A.; Chang Claude, J.(58/140). 2020. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk.Journal of the National Cancer Institute. ISSN 1460-2105.

12 Escala Garcia, M.; Abraham, J.; Andrulis, IL.; et al; González Neira, A.; Schmidt, MK.(56/145). 2020. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.Nature communications. 11-1, pp.312. ISSN 2041-1723.

13 Montero Conde, C.; Graña Castro, O.; Martín Serrano, G.; et al; González Neira, A.; Robledo, M.(27/32). 2020. Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing.International journal of cancer. 146-2, pp.521-530. ISSN 1097-0215.

14 Fachal, L.; Aschard, H.; Beesley, J.; et al; González Neira, A.; Dunning, AM.(118/341). 2020. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.Nature genetics. 52-1, pp.56-73. ISSN 1546-1718.

15 Trivino, J. C.; Ceba, A.; Rubio-Solsona, E.; et al; Benitez, J.2020. Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control study BMC CANCER. 20.

16 Lin, SH.; Sampson, JN.; Grünewald, TGP.; et al; González Neira, A.; Machiela, MJ.(18/56). 2020. Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma.PloS one. 15-9, pp.e0237792. ISSN 1932-6203.

17 García Romero, N.; Carrión Navarro, J.; Areal Hidalgo, P.; et al; González Neira, A.; Ayuso Sacido, A.(8/12). 2019. V600E Detection in Liquid Biopsies from Pediatric Central Nervous System Tumors Cancers. 12-1. ISSN 2072-6694.

18 Ferreira, MA.; Gamazon, ER.; Al Ejeh, F.; et al; González Neira, A.; Chenevix Trench, G.(79/210). 2019. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.Nature communications. 10-1, pp.1741. ISSN 2041-1723.

19 Escala Garcia, M.; Guo, Q.; Dörk, T.; et al; González Neira, A.; Schmidt, MK.(81/236). 2019. Genome-wide association study of germline variants and breast cancer-specific mortality.British journal of cancer. 120-6, pp.647-657. ISSN 1532-1827.

20 Wu, L.; Shi, W.; Long, J.; et al; Zheng, W.2018. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer.Nature genetics. 50-7, pp.968-978. ISSN 1546-1718.

21 Sara Ruiz-Pinto; Guillermo Pita; Miguel Martín; Teresa Alonso-Gordoa. (17/17). 2018. Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients Breast Cancer Res Treat.Jan;167(1):249-256.

22 Sara Ruiz-Pinto; Guillermo Pita; Ana Patiño; Javier Alonso. (17/17). 2017. Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer Pharmacogenet Genomics. Dec;27(12):445-453.

23 2017. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer Nat Genet.Dec;49(12):1767-1778.

24 2017. Association analysis identifies 65 new breast cancer risk loci Nature. Nov 2;551(7678):92-9.

25 Lawrenson, K.; Kar, S.; McCue, K.; et al; González Neira, A.; Gayther, SA.(99/282). 2016. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.Nature communications. 7, pp.12675. ISSN 2041-1723.

26 Ruiz Pinto, S.; Pita, G.; Patiño García, A.; et al; González Neira, A. (AC). (19/19). 2016. Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome.Annals of oncology. 27-9, pp.1788-1793. ISSN 1569-8041.

27 Dunning, AM.; Michailidou, K.; Kuchenbaecker, KB.; et al; González Neira, A.; Edwards, SL.(45/248). 2016. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.Nature genetics. 48-4, pp.374-386. ISSN 1546-1718.

28 Day, FR.; Ruth, KS.; Thompson, DJ.; et al; Murray, A.2015. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair.Nature genetics. 47-11, pp.1294-1303. ISSN 1546-1718.

29 Michailidou, K.; Beesley, J.; Lindstrom, S.; et al; González Neira, A.; Easton, DF.(99/243). 2015. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.Nature genetics. 47-4, pp.373-380. ISSN 1546-1718.

30 Garcia Closas, M.; Couch, FJ.; Lindstrom, S.; et al; Kraft, P.2013. Genome-wide association studies identify four ER negative-specific breast cancer risk loci.Nature genetics. 45-4, pp.392. ISSN 1546-1718.
31 Michailidou, K.; Hall, P.; Gonzalez Neira, A.; et al; Easton, DF.(2/219). 2013. Large-scale genotyping identifies 41 new loci associated with breast cancer risk.Nature genetics. 45-4, pp.353. ISSN 1546-1718.
32 Bojesen, SE.; Pooley, KA.; Johnatty, SE.; et al; Dunning, AM.2013. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.Nature genetics. 45-4, pp.371. ISSN 1546-1718.

C.3. Proyectos y Contratos

1 **Proyecto**. Transcriptome-wide association study of breast cancer women: a new strategy to identify novel risk genes for anthracycline-induced cardiotoxicity in the era of precision medicine. (Centro Nacional de Investigaciones Oncológicas). 01/01/2022-31/12/2024. 62.920 €.
2 **Proyecto**. Proyecto IMPaCT (Infraestructura de Medicina de Precisión asociada a la Ciencia y Tecnología (IMPaCT)- Programa Medicina Genomica. (Centro Nacional de Investigaciones Oncológicas). 01/01/2021-31/12/2023.
3 **Proyecto**. Role of the mitochondrial genes in cardiotoxicity: identification of predictive biomarkers. (Centro Nacional de Investigaciones Oncológicas). 01/01/2019-31/12/2021. 111.320 €.
4 **Proyecto**. Biomolecular and Bioinformatics Resources Platform (Plataforma de Recursos Biomoleculares y Bioinformáticos PRB3 PT17/0019/0020. Javier Benitez Ortiz. (Centro Nacional de Investigaciones Oncológicas). 01/01/2018-31/12/2020. 635.358 €.
5 **Proyecto**. Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES). Peter Devilee. (Centro Nacional de Investigaciones Oncológicas). 2015-2020. 4.960.000 €.
6 **Proyecto**. Personalización del Tratamiento del Cáncer de Mama: construcción de un modelo predictor de eficacia a taxanos y antraciclinas mediante integración de diversas aproximaciones genomicas. Ministerio de Ciencia e Innovación. Investigación. Anna Gonzalez Neira. (Centro Nacional de Investigaciones Oncológicas). 2013-2016. 100.430 €.
7 **Proyecto**. Farmacogenética en tumores infantiles. Asociación Española Contra el Cáncer. Anna Gonzalez Neira. (Centro Nacional de Investigaciones Oncológicas). 2011-2014. 150.000 €.
8 **Proyecto**. Collaborative Oncological Gene-environment Study (COGS).. CENTRO DE ACUSTICA APLICADA Y EVALUACION NO DESTRUCTIVA. Per Hall. (Centro Nacional de Investigaciones Oncológicas). 2009-2013. 2.300.650,68 €.
9 **Proyecto**. Susceptibilidad genética: riesgo de cáncer de mama y consumo de bebidas alcohólicas en España. Fundación Sandra Ibarra Ayudas a la Investigación en cáncer de mama. Miguel Martín Jiménez. (Centro Nacional de Investigaciones Oncológicas). 2011-2012. 25.000 €.
10 **Proyecto**. Modelos animales para el estudio de enfermedades de la visión.. Convocatoria de programas de i+d en biomedicina. Lluis Montoliu. (Centro Nacional de Investigaciones Oncológicas). 2010-2012. 278.000 €.
11 **Proyecto**. Determinación de polimorfismos asociados al riesgo de desarrollar cáncer de pulmón en individuos con fenotipos extremos mediante GWAS.. Becas de proyectos de investigación de la Sociedad Española de Oncología Médica. José Luis Pérez Gracia. (Centro Nacional de Investigaciones Oncológicas). 2011-2011. 15.000 €.
12 **Proyecto**. Farmacogenética en tumores infantiles. Fundación Inocente Inocente. Anna Gonzalez Neira. (Centro Nacional de Investigaciones Oncológicas). 2009-2009. 30.000 €.